Lassogen, Inc.

Lassogen, Inc. is a preclinical biotechnology company based in San Diego, California, founded in 2019.

The company focuses on developing innovative therapeutics using engineered lasso peptides, referred to as "Lassotides." These programmable medicines combine the targeting precision of antibodies with the cellular penetration of small molecules, aiming to address challenges in immuno-oncology and other serious diseases. Lassogen's team consists of experts in biotechnology and drug development, leveraging over 100 years of collective experience. The company is advancing its therapeutic pipeline, which includes candidates like LAS-103, targeting specific cancer receptors. Lassogen also offers B2B services in drug discovery and development, synthetic biology, and AI-driven analytics, collaborating with pharmaceutical companies, biotech firms, and research institutions to create effective treatment options.